Skip to main content

Loading market data...

BBIO

BridgeBio Pharma, Inc.

NASDAQ • United states

$67.45

-$0.50

(-0.73%)

Source: Yahoo Finance · Quote time Oct 20, 2026 16:48 GMT+0000

Management
Credibility
Score

BridgeBio Pharma, Inc. (BBIO)

Unavailable

Quotes may be delayed

$13.18B

Market Cap

1,152,142

Volume

Unavailable

P/E Ratio

Unavailable

Div Yield

BridgeBio Pharma, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 3160 PORTER DR., PALO ALTO, CA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

13 Oct 2026

BridgeBio Pharma, Inc. reported Another company event

BridgeBio Pharma, Inc. filed an 8-K covering another company event, supporting financial statements or exhibits.

31 Aug 2026

BridgeBio Pharma, Inc. reported Another company event

BridgeBio Pharma, Inc. filed an 8-K covering another company event, supporting financial statements or exhibits.

18 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in BridgeBio Pharma, Inc..

17 Aug 2026

BridgeBio Pharma, Inc. reported A material agreement

BridgeBio Pharma, Inc. filed an 8-K covering a material agreement, another company event, supporting financial statements or exhibits.

11 Aug 2026

BridgeBio Pharma, Inc. filed Form 10-Q

BridgeBio Pharma, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$677.91M

Total assets (USD)$1.22B

Total liabilities (USD)$3.72B

Shareholders' equity (USD)−$2.52B

Long-term debt (USD)$2.65B

Debt due within a year (USD)$3.65M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$243.68M	−$107.08M	−$155.89M	−$0.78	10-Q · 10 Aug 2026
Q1 2026	$194.52M	−$105.96M	−$166.56M	−$0.84	10-Q · 7 May 2026
Q4 2025	$154.18M	−$139.56M	−$194.64M	Unavailable	10-K · 24 Feb 2026
Q3 2025	$120.70M	−$145.20M	−$184.94M	−$0.95	10-Q · 29 Oct 2025
Q2 2025	$110.57M	−$134.28M	−$183.76M	−$0.95	10-Q · 5 Aug 2025
Q1 2025	$116.63M	−$104.37M	−$169.61M	−$0.88	10-Q · 29 Apr 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $110.24

63.5% upside potential

📈

Strong Buy

Unavailable

👍

Buy

17

⏸️

Hold

1

📉

Sell

0

18 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 20 Oct 2026, 16:49 UTC Targets range 91.00–156.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

17

Sep 2026

Kumar Neil

Director, Chief Executive Officer

Open-market sale

$69.08 per share

10,000 shares

19

Aug 2026

Kumar Neil

Director, Chief Executive Officer

Open-market sale

$84.03 per share

10,000 shares

18

Aug 2026

Kumar Neil

Director, Chief Executive Officer

Open-market sale

$82.53 per share

34,980 shares

16

Aug 2026

Trimarchi Thomas

President and CFO

Tax withholding

$79.86 per share

22,781 shares

16

Aug 2026

Kumar Neil

Director, Chief Executive Officer

Option exercise

Unavailable per share

71,217 shares

16

Aug 2026

Kumar Neil

Director, Chief Executive Officer

Tax withholding

$79.86 per share

36,237 shares

16

Aug 2026

Apuli Maricel

Chief Accounting Officer

Tax withholding

$79.86 per share

4,714 shares

30

Jul 2026

Apuli Maricel

Chief Accounting Officer

Open-market sale

$80.06 per share

2,000 shares

9

Jul 2026

Ellis Andrea

Director

Option exercise

$16.75 per share

17,167 shares

9

Jul 2026

Ellis Andrea

Director

Open-market sale

$84.00 per share

17,167 shares

Top Shareholders

Vanguard Group Inc

16,862,691 shares

0.182% change

12/31/2025

Jupiter Topco Llc

14,110,278 shares

New% change

6/30/2026

Kohlberg Kravis Roberts & Co. L.P.

13,260,971 shares

0% change

6/30/2026

Janus Henderson Group Ltd.

13,179,013 shares

19.804% change

3/31/2026

Farallon Capital Management, L.L.C.

10,743,063 shares

14.709% change

6/30/2026

Blackrock, Inc.

10,287,156 shares

-27.595% change

6/30/2026

Viking Global Investors Lp

9,949,219 shares

-15.987% change

6/30/2026

Vanguard Capital Management Llc

7,898,973 shares

1.798% change

6/30/2026

Vanguard Portfolio Management Llc

7,656,722 shares

-5.245% change

6/30/2026

Wellington Management Group Llp

5,308,924 shares

113.729% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 20 Oct 2026, 16:49 UTC· 1 day ago

Research coverage and investment tools

BridgeBio Pharma, Inc. (BBIO) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$67.45 on 20 Oct 2026. That is 36% of the way from its 52-week low of US$52.75 to its 52-week high of US$93.42. Its market capitalisation was US$13.18 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$243.68M	−$107.08M	−$155.89M	−$0.78	—	-43.9%	−$71.54M	10-Q · 10 Aug 2026 (opens in a new tab)
Q1 2026	$194.52M	−$105.96M	−$166.56M	−$0.84	—	-54.5%	−$197.35M	10-Q · 7 May 2026 (opens in a new tab)
Q4 2025	$154.18M	−$139.56M	−$194.64M	Unavailable	—	-90.5%	−$56.45M	10-K · 24 Feb 2026 (opens in a new tab)
Q3 2025	$120.70M	−$145.20M	−$184.94M	−$0.95	—	-120.3%	−$110.04M	10-Q · 29 Oct 2025 (opens in a new tab)
Q2 2025	$110.57M	−$134.28M	−$183.76M	−$0.95	—	-121.4%	−$81.28M	10-Q · 5 Aug 2025 (opens in a new tab)
Q1 2025	$116.63M	−$104.37M	−$169.61M	−$0.88	—	-89.5%	−$199.24M	10-Q · 29 Apr 2025 (opens in a new tab)

Cash and equivalents: $677.91M
Total assets: $1.22B
Total liabilities: $3.72B
Shareholders' equity: −$2.52B
Long-term debt: $2.65B
Debt due within a year: $3.65M

8-K · 13 Oct 2026

BridgeBio Pharma, Inc. reported Another company event (opens in a new tab)

BridgeBio Pharma, Inc. filed an 8-K covering another company event, supporting financial statements or exhibits.
8-K · 31 Aug 2026

BridgeBio Pharma, Inc. reported Another company event (opens in a new tab)

BridgeBio Pharma, Inc. filed an 8-K covering another company event, supporting financial statements or exhibits.
SCHEDULE 13D/A · 18 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in BridgeBio Pharma, Inc..
8-K · 17 Aug 2026 · Material agreement Signed

BridgeBio Pharma, Inc. reported A material agreement (opens in a new tab)

BridgeBio Pharma, Inc. filed an 8-K covering a material agreement, another company event, supporting financial statements or exhibits.
10-Q · 11 Aug 2026

BridgeBio Pharma, Inc. filed Form 10-Q (opens in a new tab)

BridgeBio Pharma, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

Insider	Date	Transaction	Shares	Average price	Filing
Kumar Neil Director, Chief Executive Officer	17 Sep 2026	Open-market sale (S)	−10,000	$69.08	Form 4 (opens in a new tab)
Kumar Neil Director, Chief Executive Officer	19 Aug 2026	Open-market sale (S)	−10,000	$84.03	Form 4 (opens in a new tab)
Kumar Neil Director, Chief Executive Officer	18 Aug 2026	Open-market sale (S)	−34,980	$82.53	Form 4 (opens in a new tab)
Trimarchi Thomas President and CFO	16 Aug 2026	Tax withholding (F)	−22,781	$79.86	Form 4 (opens in a new tab)
Kumar Neil Director, Chief Executive Officer	16 Aug 2026	Option exercise (M)	+71,217	—	Form 4 (opens in a new tab)
Kumar Neil Director, Chief Executive Officer	16 Aug 2026	Tax withholding (F)	−36,237	$79.86	Form 4 (opens in a new tab)
Apuli Maricel Chief Accounting Officer	16 Aug 2026	Tax withholding (F)	−4,714	$79.86	Form 4 (opens in a new tab)
Apuli Maricel Chief Accounting Officer	30 Jul 2026	Open-market sale (S)	−2,000	$80.06	Form 4 (opens in a new tab)
Ellis Andrea Director	9 Jul 2026	Option exercise (M)	+17,167	$16.75	Form 4 (opens in a new tab)
Ellis Andrea Director	9 Jul 2026	Open-market sale (S)	−17,167	$84.00	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Vanguard Group Inc	12/31/2025	16,862,691	0.182%
Jupiter Topco Llc	6/30/2026	14,110,278	New
Kohlberg Kravis Roberts & Co. L.P.	6/30/2026	13,260,971	0%
Janus Henderson Group Ltd.	3/31/2026	13,179,013	19.804%
Farallon Capital Management, L.L.C.	6/30/2026	10,743,063	14.709%
Blackrock, Inc.	6/30/2026	10,287,156	-27.595%
Viking Global Investors Lp	6/30/2026	9,949,219	-15.987%
Vanguard Capital Management Llc	6/30/2026	7,898,973	1.798%
Vanguard Portfolio Management Llc	6/30/2026	7,656,722	-5.245%
Wellington Management Group Llp	6/30/2026	5,308,924	113.729%

Previous close: 67.94 USD
Day range: 67.39 – 69.00 USD
52-week range: 52.75 – 93.42 USD
Volume: 1,152,142
Market cap: $13.18B
Average volume: 2,492,271
EPS (FY 2025, diluted): −3.78 USD
Shares outstanding: 195.49M
Beta (5Y monthly): 0.96

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 16:48 UTC· 1 day ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:19 UTC· 53 minutes ago

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for BBIO yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.